Viridian Therapeutics, Inc. (VRDN) – What Are Investment Firms Saying About This Stock?

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have been given a consensus rating of “Moderate Buy” by the twelve research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $38.92.

VRDN has been the topic of several recent analyst reports. Truist Financial raised their target price on Viridian Therapeutics from $38.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Wedbush upped their price target on Viridian Therapeutics from $32.00 to $43.00 and gave the company an “outperform” rating in a research report on Tuesday, June 30th. The Goldman Sachs Group reiterated a “buy” rating and issued a $39.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, June 30th. Weiss Ratings upgraded Viridian Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 14th. Finally, Wall Street Zen lowered Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Sunday, October 4th.

Insider Activity at Viridian Therapeutics

In related news, insider Jennifer Tousignant sold 14,212 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total transaction of $348,194.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Viridian Therapeutics

Large investors have recently added to or reduced their stakes in the stock. AMI Asset Management Corp purchased a new position in shares of Viridian Therapeutics during the 3rd quarter worth approximately $1,029,000. Integrated Wealth Concepts LLC bought a new position in shares of Viridian Therapeutics in the 2nd quarter worth approximately $33,000. Squarepoint Ops LLC lifted its stake in shares of Viridian Therapeutics by 303.0% in the 2nd quarter. Squarepoint Ops LLC now owns 176,955 shares of the company’s stock valued at $3,251,000 after purchasing an additional 133,046 shares during the period. Arizona State Retirement System lifted its stake in shares of Viridian Therapeutics by 19.2% in the 2nd quarter. Arizona State Retirement System now owns 21,330 shares of the company’s stock valued at $392,000 after purchasing an additional 3,431 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Viridian Therapeutics in the 2nd quarter valued at approximately $204,000.

Viridian Therapeutics Price Performance

Shares of Viridian Therapeutics stock opened at $22.37 on Friday. The company’s fifty day simple moving average is $21.62 and its two-hundred day simple moving average is $18.96. Viridian Therapeutics has a 12-month low of $13.18 and a 12-month high of $34.29. The firm has a market cap of $2.53 billion, a PE ratio of -6.64 and a beta of 1.11. The company has a quick ratio of 16.95, a current ratio of 16.95 and a debt-to-equity ratio of 0.43.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.02). The firm had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.06 million. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. As a group, equities analysts expect that Viridian Therapeutics will post -4.07 EPS for the current year.

About Viridian Therapeutics

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company’s lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian’s pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.